Please provide your email address to receive an email when new articles are posted on . Denifanstat, a fatty acid synthase inhibitor, was effective in the treatment of moderate to severe acne vulgaris ...

Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026 Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion More ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A multi-center, prospective, open-label, single arm ...

SAN MATEO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and ...

Acne vulgaris is one of the commonest skin disorders, which dermatologists treat and it mainly affects adolescents, though it may appear at any age. Acne by definition is multifactorial chronic ...

The treatment of acne ( Table I) [1,2,3,4,5,6] is based upon its severity (mild, moderate, severe) and the type(s) of lesion(s) present (noninflammatory, inflammatory, mixed). In general, the ...

Severe acne is more than just an inconvenience — it is stubborn, requires a dermatologist's care, and can be extremely painful, leaving emotional and physical scars in its wake. Those who experience ...

Acne vulgaris is a multifactorial skin disorder marked by inflammatory and non-inflammatory lesions that can cause significant physical and psychological distress. Traditional treatment options, ...

Active ingredients: Clindamycin (as phosphate) 1.2%, benzoyl peroxide 2.5%; gel. Indication: Topical treatment of acne vulgaris. Pharmacology: Acanya gel combines the lincosamide antibiotic, ...

The Accure Laser System is the next generation light-based platform for the treatment of acne. The Accure Laser is the first 1726nm-based laser platform with both FDA and CE Mark clearances. "I see ...

WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), received ...